Animal Modeling of Pediatric Liver Cancer
Hepatoblastoma (HB) is the most common pediatric liver malignancy. Management of HB requires multidisciplinary efforts. The 5-year overall survival of this disease is about 80% in developed countries. Despite advances in the care of these patients, survival in recurrent or treatment-refractory disea...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/2/273 |
| _version_ | 1797711889709400064 |
|---|---|
| author | Richard S. Whitlock Tianyou Yang Sanjeev A. Vasudevan Sarah E. Woodfield |
| author_facet | Richard S. Whitlock Tianyou Yang Sanjeev A. Vasudevan Sarah E. Woodfield |
| author_sort | Richard S. Whitlock |
| collection | DOAJ |
| description | Hepatoblastoma (HB) is the most common pediatric liver malignancy. Management of HB requires multidisciplinary efforts. The 5-year overall survival of this disease is about 80% in developed countries. Despite advances in the care of these patients, survival in recurrent or treatment-refractory disease is lower than 50%. This is due to more complex tumor biology, including hepatocellular carcinoma (HCC)-like mutations and expression of aggressive gene signatures leading to chemoresistance, vascular invasion, and metastatic spread. The current treatment protocols for pediatric liver cancer do not incorporate targeted therapies, and the ability to test these therapies is limited due to the inaccessibility of cell lines and mouse models. In this review, we discuss the current status of preclinical animal modeling in pediatric liver cancer, primarily HB. Although HB is a rare cancer, the research community has worked together to develop a range of interesting and relevant mouse models for diverse preclinical studies. |
| first_indexed | 2024-03-12T07:13:39Z |
| format | Article |
| id | doaj.art-e0992d700f4a405894328dbb12e67ad8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T07:13:39Z |
| publishDate | 2020-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e0992d700f4a405894328dbb12e67ad82023-09-02T22:57:39ZengMDPI AGCancers2072-66942020-01-0112227310.3390/cancers12020273cancers12020273Animal Modeling of Pediatric Liver CancerRichard S. Whitlock0Tianyou Yang1Sanjeev A. Vasudevan2Sarah E. Woodfield3Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Pediatric Surgical Oncology Laboratory, Texas Children’s Surgical Oncology Program, Texas Children’s Liver Tumor Program, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USADepartment of Pediatric Surgery, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, ChinaDivisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Pediatric Surgical Oncology Laboratory, Texas Children’s Surgical Oncology Program, Texas Children’s Liver Tumor Program, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USADivisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Pediatric Surgical Oncology Laboratory, Texas Children’s Surgical Oncology Program, Texas Children’s Liver Tumor Program, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USAHepatoblastoma (HB) is the most common pediatric liver malignancy. Management of HB requires multidisciplinary efforts. The 5-year overall survival of this disease is about 80% in developed countries. Despite advances in the care of these patients, survival in recurrent or treatment-refractory disease is lower than 50%. This is due to more complex tumor biology, including hepatocellular carcinoma (HCC)-like mutations and expression of aggressive gene signatures leading to chemoresistance, vascular invasion, and metastatic spread. The current treatment protocols for pediatric liver cancer do not incorporate targeted therapies, and the ability to test these therapies is limited due to the inaccessibility of cell lines and mouse models. In this review, we discuss the current status of preclinical animal modeling in pediatric liver cancer, primarily HB. Although HB is a rare cancer, the research community has worked together to develop a range of interesting and relevant mouse models for diverse preclinical studies.https://www.mdpi.com/2072-6694/12/2/273hepatoblastomachildrenmouse modelxenograftpatient-derived xenograft |
| spellingShingle | Richard S. Whitlock Tianyou Yang Sanjeev A. Vasudevan Sarah E. Woodfield Animal Modeling of Pediatric Liver Cancer Cancers hepatoblastoma children mouse model xenograft patient-derived xenograft |
| title | Animal Modeling of Pediatric Liver Cancer |
| title_full | Animal Modeling of Pediatric Liver Cancer |
| title_fullStr | Animal Modeling of Pediatric Liver Cancer |
| title_full_unstemmed | Animal Modeling of Pediatric Liver Cancer |
| title_short | Animal Modeling of Pediatric Liver Cancer |
| title_sort | animal modeling of pediatric liver cancer |
| topic | hepatoblastoma children mouse model xenograft patient-derived xenograft |
| url | https://www.mdpi.com/2072-6694/12/2/273 |
| work_keys_str_mv | AT richardswhitlock animalmodelingofpediatriclivercancer AT tianyouyang animalmodelingofpediatriclivercancer AT sanjeevavasudevan animalmodelingofpediatriclivercancer AT sarahewoodfield animalmodelingofpediatriclivercancer |